Carbon Nanomaterials as Carriers for the Anti-Cancer Drug Doxorubicin-A review on Theoretical and Experimental Studies

Gayathri K,Vidya Ravindran
DOI: https://doi.org/10.1039/d4na00278d
IF: 5.598
2024-04-28
Nanoscale Advances
Abstract:The incidence of cancer is increasing worldwide in a life-threatening way. In such a scenario, the development of anti-cancer drugs with minimal side effects and effective drug delivery systems become paramount importance. Doxorubicin (Dox) is one of the powerful anti-cancer drugs from the chemical family of anthracycline which is used to treat a wide variety of cancers including breast, prostate, ovary, and hematological malignancies, etc. However, DOX has been associated with many side effects including lethal cardiotoxicity, baldness, gastrointestinal disturbances and cognitive function impairment, etc. Even though DOX is administered in liposomal formulations to reduce its toxicity and enhance its therapeutic profile, the liposomal formulations themselves have certain therapeutic profile limitations like "Palmar Plantar Erythrodysthesia(PPE)" which shows severe swelling and redness in the skin restricting the dosage and reduces the patient compliance. In contemporary chemotherapy research, there is a great interest in the utilization of nanomaterials for precise and targeted drug delivery applications, especially using carbon-based nanomaterials. This review provides a comprehensive overview of both experimental and theoretical scientific works, exploring diverse forms of carbon-based materials such as graphene, graphene oxide, and carbon nanotubes that function as carriers for DOX. In addition, the review consolidates information on the fate of the carriers after the delivery of the payload in the site of action through different imaging techniques, and the various pathways through which the body eliminates these nanomaterials are also described. In conclusion, it presents a detailed overview of the associated toxicities of these carriers within the human body, contributing to the development of enhanced drug delivery systems.
materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
What problem does this paper attempt to address?
The paper primarily focuses on addressing the side effects of the anti-tumor drug Doxorubicin (DOX) in cancer treatment and improving its targeted delivery efficiency. DOX is an effective drug widely used to treat various cancers, including breast cancer, prostate cancer, ovarian cancer, and hematologic malignancies. However, DOX has severe side effects, such as cardiotoxicity, hair loss, gastrointestinal discomfort, and cognitive dysfunction. Although liposomal formulations can reduce its toxicity, these formulations themselves have limitations, such as Palmar Plantar Erythrodysthesia (PPE), which causes severe swelling and redness of the skin, limiting the dosage and reducing patient tolerance. The paper reviews the research progress of carbon nanomaterials as carriers for DOX, exploring the applications of various forms of carbon-based materials (such as graphene, graphene oxide, and carbon nanotubes) in precise and targeted drug delivery. Through theoretical and experimental studies, it demonstrates how these carbon-based materials can effectively load DOX and accumulate in the tumor microenvironment, thereby enhancing the drug's efficacy and reducing side effects. Additionally, the paper discusses the tracking of these carriers' fate and in vivo elimination pathways using different imaging techniques after delivery, and it provides a detailed overview of the related toxicity of these carriers in the human body, offering important references for developing more efficient drug delivery systems.